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After maternal predetermination gives way to zygotic regulation, a ground state is established within the
mammalian embryo. This tabula rasa for embryogenesis is present only transiently in the preimplantation
epiblast. Here, we consider how unrestricted cells are first generated and then prepared for lineage commit-
ment.We propose that two phases of pluripotency can be defined: naive and primed. This distinction extends
to pluripotent stem cells derived from embryos or by molecular reprogramming ex vivo.Mammalian embryos produce extraembryonic cells prior to
defining the founder population for the embryo proper (Gardner,
1983; Selwood and Johnson, 2006). The primary role of the
extraembryonic lineages is to mediate uterine implantation and
subsequent maternal sustenance of the growing embryo and
fetus. In recent years, it has been discovered that extraembry-
onic tissues also supply powerful inductive signals that specify
and pattern early development (Beddington and Robertson,
1999). To form the embryo, a pool of uncommitted cells must
be established and poised to respond to those signals. This pop-
ulation is the epiblast. Generation of naive epiblast several days
after fertilization is a process unique to the mammalian life cycle.
This progression does not occur through simple inheritance from
the fertilized egg, nor is epiblast specified by segregation of
maternal determinants. How the emerging epiblast is shielded
from extraembryonic differentiation and concomitantly gains
the capacity to generate all cell types of the fetus and subse-
quent adult, including the germ cells, are fundamental questions
in mammalian development. Moreover, the aspiration to exploit
ex vivo pluripotent stem cells for biomedical benefit surely
requires elucidation of their precise nature and relationship to
pluripotent cells in the embryo.
The Limitation of Totipotency
The fertilized mammalian embryo initially undergoes cleavage
division in a stereotypic fashion that is unresponsive to extrinsic
perturbation. After a fixed number of cell cycles, the individual
blastomeres become compacted together, and those on the
outside begin to form an epithelium, the trophoblast (Selwood
and Johnson, 2006). The resulting structure with an internalized
group of cells is called the blastocyst. Up to the time of
blastocyst formation, the fate of individual cells can be altered
by changing their position within the embryo (Hillman et al.,
1972). Transplantation studies confirm that single blastomeres
have the potential to generate both extraembryonic and embry-
onic lineages (Gardner, 1998). Moreover, normal development
can ensue following removal of one or more cells from the
8- or 16-cell embryo. This adaptability is exploited in a clinical
setting to allow for pregestational diagnosis of severe genetic
disease. These findings argue persuasively against an essentialrole for asymmetric segregation of determinants inherited from
the egg.
Because it can give rise to an entire embryo, the mammalian
egg is often described as totipotent. However, this description
does not mean that the egg itself has the ability to differentiate
into all cell types. In reality, the mammalian zygote follows
a determined programof restricted differentiation. If blastomeres
are dissociated, they divide and differentiate on schedule to form
trophoblast vesicles or microblastocysts with as few as 2 cells
(Tarkowski and Wroblewska, 1967; Ziomek and Johnson,
1980). Thus, the egg and blastomeres produce directly only
two cell types, the trophoblast and the inner cell mass (ICM).
For subsequent development, cells within the ICM must acquire
the capacity to generate other cell types and to do so in a flexible
manner (Gardner and Beddington, 1988). The ICM produces
a second extraembryonic lineage, the hypoblast, and around
the same time, the remaining cells develop into pluripotent
epiblast. The epiblast is functionally and molecularly distinct
from blastomeres and early inner cell mass (Gardner, 1998;
Kaji et al., 2007; Kurimoto et al., 2006). Formation of the blasto-
cyst is a deterministic preparatory process dictated by the
requirement to elaborate extraembryonic tissues. In comparison
with development in other vertebrates, this period may be
viewed as a preembryonic stage (Selwood and Johnson,
2006). Thus, rather than representing a diminution in potency
from the egg, we suggest that the epiblast constitutes the ground
state, meaning a fully unrestricted population that harbors the
requisite developmental potency and flexibility to produce all
embryonic lineages.
Regulative Development and Stem Cell Character
The early mammalian embryo has a remarkable ability to ac-
commodate alterations in cell numbers. Additional cells can be
introduced into preimplantation embryos and will readily be
incorporated into normal development, resulting in chimeric
animals. In more extreme examples, miniblastocysts, produced
by separating 2-cell embryos, or giant blastocysts, generated
by combining two or more cleavage stage embryos, develop
into normal-sized fetuses and viable animals. This regulative
capacity is reminiscent of the flexibility associatedwith stemcells
(Gardner and Beddington, 1988). The finding that progenitors ofCell Stem Cell 4, June 5, 2009 ª2009 Elsevier Inc. 487
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epiblast—can be propagated continuously in vitro (Rossant,
2008) is consistent with an underlying element of stem cell
character. Importantly, however, this plasticity does not extend
to transdetermination across lineages. How extraembryonic
lineage segregation is secured while pluripotency develops in
adjacent cells are intertwined issues in preimplantation develop-
ment (Niwa, 2007).
The Ground State and True Embryonic Stem Cells
The newly formed epiblast is a cluster of 10–20 unspecialized
cells sandwiched between the trophoblast and the hypoblast
(Figures 1 and 2). The epiblast generates the entire fetus and
single mouse epiblast cells, isolated at this stage and microin-
jected into another blastocyst, can contribute to all lineages
Figure 1. Two Phases of Pluripotency
Ground state naive pluripotency is established in the epiblast of the mature
blastocyst and may be captured in vitro in the form of ESCs. Shortly after
implantation, the epiblast transforms into a cup-shaped epithelium and
becomes primed for lineage specification and commitment in response to
stimuli from the extraembryonic tissues. EpiSCs are the in vitro counterpart
of primed epiblast. ESCs can be induced to differentiate into EpiSCs by expo-
sure to activin and Fgf, but the reverse transition requires transfection with Klf4
or other reprogramming factors.
Upper images show mouse embryos at E4.5 and E5.5, or shortly before and
shortly after implantation. The white asterisks indicate the epiblast. Note the
layer of hypoblast underlying the epiblast in the blastocyst and the proamniotic
cavity surrounded by epiblast in the postimplantation embryo. The epiblast is
displaced downward after implantation due to proliferation of the trophecto-
derm-derived extraexembryonic ectoderm and the constraint of the uterine
wall. Lower images show representative colonies of ESCs and EpiSCs. See
Batlle-Morera et al. (2008) and Guo et al. (2009) for details of embryo dissec-
tion, ESC and EpiSC culture, and photography.488 Cell Stem Cell 4, June 5, 2009 ª2009 Elsevier Inc.(Gardner, 1998). Functionally, therefore, preimplantation
epiblast is the developmental ground state.
Embryonic stem cells (ESCs) can be derived at this point
(Evans and Kaufman, 1981; Martin, 1981). ESCs represent
immortalization of the naive epiblast. Under appropriate condi-
tions, they exhibit unlimited self-renewal capacity while retaining
the attributes of preimplantation epiblast identity and potency.
Specifically, when returned to the blastocyst, ESCs are readily
incorporated into the epiblast and re-enter embryonic develop-
ment to produce functional soma and germ cells (Bradley
et al., 1984). ESCs also share an epigenetic feature with preim-
plantation epiblast. This shared trait is the presence of two active
X chromosomes in female cells. In female embryos, the pater-
nally inherited X chromosome is silenced during cleavage and
remains silent in extraembryonic lineages. Reactivation occurs
transiently in the pluripotent lineage prior to implantation (Heard,
2004). X chromosome activation not only provides an epigenetic
signature of ground state pluripotency but, in females, is critical
to allow for random inactivation in the soma and, thus, avoid
functional hemizygosity.
The epiblast has been identified unequivocally as a source of
ESCs by means of microsurgical separation from trophoblast
and hypoblast prior to culture (Batlle-Morera et al., 2008; Brook
and Gardner, 1997). These experiments also suggested that
removal of the extraembryonic tissuesmay facilitate ESC deriva-
tion. ESCs have also been obtained frommouse embryos placed
in culture prior to epiblast formation, which has sown some
confusion as to their precise origin and identity. It should be
borne in mind, however, that embryonic cells are not frozen at
the stage when they are put in culture but may continue to follow
a developmental program. Thus, cells may progress to the
epiblast stage even if isolated from earlier stage embryos.
Indeed, mouse ESC lines are molecularly and phenotypically
alike, however they have been derived.
The original key to success in deriving ESCs was coculture
with mouse embryo fibroblasts, now known to produce the cyto-
kine leukemia inhibitory factor (Lif). Lif activates the transcription
factor Stat3, which inhibits ESC differentiation and promotes
viability (Smith, 2001). Genetic and biochemical studies have
indicated that stimulation of the Erk pathway by Fgf4 and other
extrinsic stimuli is a signal that primes ESCs for lineage specifi-
cation (Burdon et al., 1999; Kunath et al., 2007; Stavridis et al.,
2007). Recently it has been found that blockade of this pathway
and ancillary suppression of glycogen synthase kinase-3 (Gsk3)
with selective small molecule inhibitors (3i or 2i) is sufficient to
stabilize and sustain ESCswith full pluripotency (Silva and Smith,
2008; Ying et al., 2008). In our experience, all ESCs, however
derived or previously cultured, can be propagated in serum-
free culture using these inhibitors with optional addition of Lif.
We, therefore, propose that independence from Erk signaling
may be a biochemical correlate of the ground state. In line with
this idea, use of 2i plus Lif facilitates the isolation of authentic
induced pluripotent stem cell (iPSC) lines with full pluripotent
capacity (Guo et al., 2009; Silva et al., 2008; Sridharan et al.,
2009). This competence appears to be mediated through
a combination of both selection for and stabilization of the
ground state (Silva et al., 2008; Silva and Smith, 2008).
An issue that remains unresolved is whether the derivation of
ESCs may entail some reversible epigenetic adaptation to the
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ESCs created in vitro or are they captured directly from the
epiblast? By plating dissociated cells, a maximum of three inde-
pendent ESC clones have been established from a single
epiblast (Brook and Gardner, 1997). These authors suggest
that only a subset of cells within the epiblast may be truly plurip-
otent and consequently capable of producing ESCs. Relatively
low efficiency, and pronounced differences in ability to derive
ESCs between mouse strains, could also be due to a limiting
epigenetic reprogramming step. Revisiting this experiment using
the 3i/2i culture conditions will test the hypothesis of a common
ground state both within the preimplantation epiblast and
between epiblast and ESCs. We speculate that epiblast cells
resident in the blastocyst are in a similar biochemical state to
ESCs and may require little or no adaptation to culture if insu-
lated from Erk signaling.
The Primed Pluripotent State and ‘‘Human ESCs’’
After uterine implantation, the rodent epiblast converts into
a single-cell layer of columnar epithelium (Kaufman, 1992). This
conversion is associated with a morphological transformation
into a cup-shaped structure known as the egg cylinder (Figure 1).
In XX embryos, one of the X chromosomes undergoes random
inactivation in early egg cylinder epiblast cells (Heard, 2004).
The epiblast is then subject to a systematic topological
bombardment with inductive factors emanating from the adja-
cent yolk sac and trophoblast tissue (Beddington and Robert-
son, 1999). These molecules include fibroblast growth factors,
bone morphogenetic proteins, Wnts, and their respective antag-
onists. Egg cylinder epiblast cells, therefore, become instruc-
Figure 2. The Ground State Epiblast in the Mouse Blastocyst
Confocal image of a diapause blastocyst immunostained for Nanog (green)
and Oct4 (pink), showing that the ICM is partitioned between Nanog-positive
epiblast and Nanog-negative hypoblast. Oct4 is present in all ICM cells. The
epiblast is entirely surrounded by trophoblast and hypoblast. Blue is DAPI
staining of cell nuclei. See Batlle-Morera et al. (2008) for details of immunos-
taining and imaging.tively specified according to their location. Transplantations
between egg cylinders indicate that fates can still be altered at
this stage (Gardner and Beddington, 1988). However, postim-
plantation epiblast cells cannot contribute to blastocyst
chimeras (Rossant, 2008), nor can they give rise to ESCs.
Cell lines have now been derived from postimplantation
mouse epiblasts using culture conditions without Lif but
including Fgf and activin (Brons et al., 2007; Tesar et al., 2007).
These cells, termed EpiSCs, express core pluripotency factors,
Oct4, Sox2, and Nanog, but differ from ESCs in expression of
several other transcripts. EpiSCs are able to differentiate into
various cell types in vitro, but this capacity has not been studied
extensively to date. It is conceivable that EpiSC lines could be
biased in how efficiently they can be committed to different line-
ages, depending upon their inductive history in the embryo, or
defined by the EpiSC culture conditions. If so, this skewing could
offer an advantage for directed differentiation along specific line-
ages. Alternatively, any pre-existing lineage bias may be erased
in culture. However, EpiSCs are not competent to contribute to
blastocyst chimeras (Guo et al., 2009; Tesar et al., 2007) and
are, therefore, developmentally and functionally distinct from
naive epiblast and ESCs (see Table 1).
EpiSCs can also be produced from ESCs in culture (Guo et al.,
2009). This conversion fulfills the criteria for an authentic differ-
entiation process because the reverse transition has not been
observed without genetic manipulation. Consistent with a true
differentiation event, one copy of the X chromosome in XX cells
is epigenetically silenced as ESCs become EpiSCs. However,
EpiSCs still express the canonical pluripotency factors and can
be reprogrammed to naive pluripotency by transfection with
just a single factor, Klf4 (Guo et al., 2009). The resulting iPSCs
show reactivation of the X chromosome, exhibit the ESC-
specific transcriptional profile, produce high contribution
somatic chimeras, and give germline transmission.
The production of mouse EpiSCs from somatic cells bymolec-
ular reprogramming has not been reported. However, it would be
Table 1. Comparison of Naive and Primed Pluripotent States
Property Ground State Primed State
Embryonic tissue early epiblast egg cylinder or
embryonic disc
Culture stem cell rodent ESCs rodent EpiSCs;
primate ‘‘ESCs’’
Blastocyst chimaeras yes noa
Teratomas yes yes
Differentiation bias none variable
Pluripotency factors Oct4, Nanog,
Sox2, Klf2, Klf4
Oct4, Sox2, Nanog
Naive markersb Rex1, NrOb1, Fgf4 absent
Specification markers absent Fgf5, T
Response to Lif/Stat3 self-renewal none
Response to Fgf/Erk differentiation self-renewal
Clonogenicity high low
XX status XaXa XaXi
Response to 2i self-renewal differentiation/death
aNot applied to primate cells.
b Representative examples.Cell Stem Cell 4, June 5, 2009 ª2009 Elsevier Inc. 489
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using morphology or the standard Oct4-GFP reporters. It would
be interesting to know if reprogramming in Fgf and activin culture
conditions yields EpiSCs, particularly if Klf4 was excluded or
selectively silenced.
In the absence of chimeras, the standard assay to assess
pluripotency is formation of teratomas, which are tumors that
contain tissues representative of all three germlayers. Teratomas
occur naturally as germline tumors. It is surely not a coincidence
that germ cells can be reprogrammed to pluripotency in culture
without genetic manipulation (Kanatsu-Shinohara et al., 2004;
Matsui et al., 1992; Resnick et al., 1992). Before discovery of
ESCs, undifferentiated cells isolated from teratomas were found
to retain the capacity at single-cell level to reform multidifferen-
tiated tumors (Kleinsmith and Pierce, 1964; Martin, 1980). These
cancer stem cells are called embryonal carcinoma (EC) cells. A
few EC cell lines were able to contribute to chimeras, but the
majority could not, an outcome traditionally attributed to karyo-
typic abnormalities (Martin, 1980). It is possible, however, that
many EC cells are, in fact, more like EpiSCs than ESCs. It would
be interesting to attempt propagation of EC cells from teratocar-
cinomas generated from ESCs and EpiSCs, comparing ground
state ESC conditions with EpiSC conditions. The results of this
investigation could reveal whether progression through a tumor
induces conversion of the grafted cells in either direction.
A variation of the EpiSC culture regime applied to mouse
blastocysts has recently been reported to yield another type of
cell line, termed FAB-SCs (Chou et al., 2008). These cultures
propagate continuously but are unable to contribute to
chimaeras or to form teratomas. However, transfer of early
passage cultures to ESC medium containing serum factors
and Lif results in the ability to produce teratomas and, at very
low frequency, chimaeras. The authors interpret this observation
as reflective of a developmental transition and argue that there
may be multiple pluripotent states (Chou et al., 2008). This
hypothesis is an intriguing notion, even if it is difficult to compre-
hend why a cell type with no evident differentiation potential
should be described as pluripotent. An embryonic stage towhich
FAB-SCs would be counterpart is unclear. Critically, the authors
do not show data to exclude the likelihood that the FAB-SC
cultures harbor a small fraction of epiblast/ESCs that can
expand if stimulated with Lif. It is essential to test this possibility
because it is well known that residual ESCs can persist in many
coculture environments, including EpiSC culture conditions (Guo
et al., 2009).
Pluripotent cell lines have been derived from human blasto-
cysts (Thomson et al., 1998). These lines differ significantly
from mouse ESCs in their culture requirements, morphology,
clonogenicity, differentiation behavior, and molecular profile.
Furthermore, the definitive functional criterion for ESC identity,
contribution to blastocyst chimeras, cannot be applied in
human. Their designation has been based on teratoma forma-
tion, which is now shown to be a common property of ESCs
and EpiSCs. It has perhaps been unhelpful to use the descriptor
‘‘human ESCs’’ for cells that are so different from the well-
defined mouse paradigm. Indeed, it is now argued that these
human cells are analogous to rodent EpiSCs (Brons et al.,
2007; Rossant, 2008; Tesar et al., 2007). Yet, EpiSCs are ob-
tained from postimplantation epiblasts, whereas human490 Cell Stem Cell 4, June 5, 2009 ª2009 Elsevier Inc.‘‘ESCs’’ are derived from cultured blastocysts. As argued above,
embryo cells may continue to progress in culture such that
human blastocyst cells may reach postimplantation epiblast
status from which EpiSCs can be derived. But why should this
transition occur in primate embryo cultures when rodent
embryos produce ESCs rather than EpiSCs?
Species Restriction to Propagation of Ground State
Pluripotency?
Ever since the first ESCs were derived from mouse blastocysts,
strenuous efforts have been made to establish pluripotent stem
cell lines from other mammals. These attempts have, in general,
been unsuccessful. Until recently, true ESCs had only been vali-
dated in the mouse. By inspiration or serendipity, strain 129 was
among those chosen for early attempts at mouse ESC derivation
(Evans and Kaufman, 1981). It transpires that ESCs can be
derived from 129 embryos more readily than from any other
mouse strain (Gardner and Brook, 1997). Substrains of 129
exhibit an elevated tendency to develop testicular carcinomas,
but it remains unclear whether this susceptibility has any
connection with the propensity to yield ESCs. Despite a range
of protocols, it remained difficult or even impossible to derive
stable chimera-competent ESC lines from most mouse strains.
The problem may simply be activation of the Erk pathway by
endogenous factors such as Fgf4 and by serum components.
Serum-free culture with inhibition of Mek and Gsk3 has facili-
tated derivation of ESCs from a range of mouse strains tested
(Ying et al., 2008). Most significantly, application of these ground
state culture conditions has broken the species barrier. Rat
ESCs capable of chimera contribution and germline transmis-
sion have finally been derived (Buehr et al., 2008; Li et al., 2008).
Nonetheless, unless or until the derivation of true ESCs from
human or other primate embryos can be verified, the validity of
the ground state hypothesis is open to question. A pertinent
issue here is that rats andmice share an unusual method of early
development. After formation of the blastocyst, other mamma-
lian embryos do not form an egg cylinder, but instead, the
epiblast delaminates as a simple flattened structure called the
embryonic disc. During formation of the rodent egg cylinder,
the epiblast cells must reorganize from a ball of cells into
a cup-shaped epithelium surrounded by hypoblast. This process
requires directed apoptosis of the internal epiblast cells (Cou-
couvanis and Martin, 1999). These events may present a hurdle
to progression out of naive pluripotency in rodent embryo
explants that extends the window for derivation of ESCs.
Conversely, in nonrodent embryo cultures, there may be no
barrier to progression to primed epiblasts, and the opportunity
for capturing the transient ground state may be minimal.
A second consideration that may mitigate against ESC deriva-
tion from primates is diapause. This is a state of arrested embry-
onic development that occurs naturally in rodents and can be
induced experimentally by lowering circulating estrogen to
prevent the uterus becoming receptive for implantation. In
diapause, embryos arrest synchronously at the late blastocyst
stage after segregation of epiblast and hypoblast (Figure 2).
Cell division is greatly reduced, indicating that pluripotency is
not intrinsically associated with rapid replication. However,
some cell turnover does occur. Therefore, the naive epiblast
seems to have an intrinsic facility for self-renewal in these
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absolute requirement for Lif/Stat3 signaling in the epiblast during
diapause (Nichols et al., 2001). This is a facultative situation,
however, because the pathway is dispensable for development
without diapause. It is conceivable that the facility for epiblast
self-renewal in diapause provides the biological foundation for
ex vivo propagation of ground state epiblast. If so, ESC deriva-
tion may be more problematic in mammals that do not exhibit
diapause, in particular if epiblasts in those species are, in conse-
quence, unresponsive to Lif/Stat3.
Molecular Requirements for Creating the Naive Ground
State
While many genes are important for viability of early embryos,
two transcriptional regulators are specifically associated with
establishing and maintaining the pluripotent compartment.
These factors are the homeodomain containing proteins Oct4
and Nanog. Oct4 is a POU domain transcription factor. It is
expressed in the ovumprior to fertilisation, and zygotic transcrip-
tion from the late 2-cell stage results in distribution to all cells
during cleavage. After blastocyst formation Oct4 is gradually
downregulated in the trophoblast (Palmieri et al., 1994). In the
late blastocyst Oct4 protein can be detected in all cells of the
epiblast. It is also expressed transiently in the hypoblast, but is
absent from all extraembryonic cells after implantation (Palmieri
et al., 1994). Thus, expression of Oct4 becomes progressively
restricted to the pluripotent compartment. Clearly, however,
Oct4 is expressed more broadly than in the epiblast and there-
fore alone cannot be sufficient to specify those cells that will
become pluripotent.
Expression of Nanog is more tightly correlated with the
nascent epiblast (Chambers et al., 2003). Nanog protein is not
maternally inherited, but first appears in a seemingly random
cellular distribution at compaction (Dietrich and Hiiragi, 2007).
As the blastocyst develops, Nanog becomes confined to the
ICM, though apparently not in all cells. Mosaic distribution in
the early ICM is suggested to be reciprocal to the distribution
of Gata6, a marker that is later specific to the hypoblast (Cha-
zaud et al., 2006). Traditionally it has been considered that
epiblast versus hypoblast fates are determined in the late ICM
based on internal or surface location, respectively (Gardner,
1983). The observation of early and mosaic expression of
Gata6 has inspired an alternative hypothesis (Chazaud et al.,
2006). Molecular specification in the early ICMmay dictate sepa-
ration into distinct territories, such that the hypoblast cells sort
out to form a cohesive epithelium overlying the epiblast.
However, it is also possible that expression of Nanog and
Gata6 may fluctuate in the early ICM and not necessarily corre-
late with any lineage specification. Indeed, chimera experiments
show that while single ICM cells have a tendency to contribute to
only hypoblast or only epiblast, a fraction of cells do contribute to
both (Chazaud et al., 2006). Furthermore, a more recent live-
imaging study points to reversibility of Gata6 expression and
suggests that at least an element of hypoblast induction is based
on cell position (Plusa et al., 2008). By whichever mechanism
the initial segregation is established, in the late blastocyst, hypo-
blast and epiblast are topologically and histologically distin-
guishable and exhibit coexclusive expression of Gata6 and
Nanog, respectively.Oct4 expression ismaintained continuously in the egg cylinder
epiblast. In contrast, Nanog is transcriptionally downregulated at
implantation (Chambers et al., 2003). Nanog is then re-ex-
pressed in the posterior egg cylinder epiblast (Hart et al.,
2004). As gastrulation proceeds and the epiblast differentiates,
both factors are extinguished in all somatic lineages (Chambers
et al., 2003;Mitsui et al., 2003). Expression persists in the primor-
dial germ cells, however (Yamaguchi et al., 2005).
Oct4 is absolutely required to establish the developmental
capacity of the ICM (Nichols et al., 1998). Without Oct4, superfi-
cially normal blastocysts form with a substantial ICM, but all the
cells assigned to the ICM domain eventually differentiate into
trophoblast. Thus, neither hypoblast nor epiblast are produced
in the absence of Oct4. Attention is generally focused on the
requirement for Oct4 to produce pluripotent cells. It is note-
worthy that internal cells in Oct4 null blastocysts transiently
exhibit features of ICM character before converting into tropho-
blast (Nichols et al., 1998). This observation might indicate that
the trophoblast differentiation is secondary to an inability to
differentiate into epiblast and hypoblast. The absolute require-
ment for Oct4 in ESCs (Niwa et al., 2000) suggests that it should
be essential for progression from ICM to epiblast. Conceivably
Oct4 might also be required for hypoblast commitment, given
its initial expression in that lineage (Palmieri et al., 1994).
Gene deletion studies have shown that, like Oct4, Nanog is
dispensable for blastocyst formation but is absolutely required
in the ICM (Mitsui et al., 2003). The ICM cells do not all differen-
tiate into trophoblast, however, pointing to a distinctive function
for Nanog compared with Oct4, consistent with their different
expression profiles. Interestingly, unlike Oct4, Nanog is dispens-
able once pluripotency has been attained in ESC cultures,
although its absence reduces the threshold for differentiation
(Chambers et al., 2007). We speculate that Nanog has a unique
function in creating the ground state and a secondary role in
stabilizing self-renewal during diapause and in ESCs (Silva and
Smith, 2008).
Conclusions and Perspectives
Development from egg to epiblast is a transition from a deter-
mined to an uncommitted state. The underlying mechanism for
acquiring pluripotency in the mammalian embryo still eludes
molecular definition. Elucidation of this process is not only of
intrinsic interest but is likely to inform understanding of molecular
reprogramming and induced pluripotent and quasipluripotent
states. Indeed, the development of ground state culture condi-
tions utilizing small molecule inhibitors of Fgf/Erk and Gsk-3
signaling has enhanced both derivation of ESCs and reprogram-
ming of somatic cells in rodents. A critical question now is
whether the ground state of pluripotency is a core feature of
mammalian embryogenesis that can allow generic isolation of
naive pluripotent stem cells from a range of species, including
human.
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